2022
Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.
Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society Of Clinical Oncology Educational Book 2022, 42: 1-14. PMID: 35486888, DOI: 10.1200/edbk_350442.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaMetastatic headCell carcinomaSystemic therapyFirst-line systemic therapyFirst-line immunotherapyInclusion of chemotherapyImmune checkpoint blockadeNew systemic therapiesNumber of patientsAggressive local managementCombination immunotherapyLocoregional therapyOligometastatic diseaseCheckpoint blockadeNovel immunotherapiesPD-L1Lung metastasesRetrospective studyBiomarker subgroupsCurrent therapiesNeck cancerAblative approachesAntiangiogenic agents
2020
Survivin expression and impact on head and neck cancer outcomes
Khan SA, Burke M, Zhu F, Yang DH, Dubyk C, Mehra R, Lango MJ, Ridge JA, Sher DJ, Burtness B. Survivin expression and impact on head and neck cancer outcomes. Oral Oncology 2020, 112: 105049. PMID: 33221541, PMCID: PMC10916757, DOI: 10.1016/j.oraloncology.2020.105049.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overApoptosisCell NucleusCyclin-Dependent Kinase Inhibitor p16CytoplasmDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm ProteinsPrognosisSex FactorsSquamous Cell Carcinoma of Head and NeckSurvivinTissue Array AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsOverall survivalSurvivin expressionTissue microarraySurvivin levelsNeck squamous cell carcinomaTotal compartmentFox Chase Cancer CenterNeck cancer outcomesShorter overall survivalSquamous cell carcinomaHigh survivin expressionGrade of tumorAnti-cancer therapySystemic therapyPatient sexSurvival outcomesCancer CenterCell carcinomaCancer outcomesP16 statusPredictive biomarkersPrimary tumorSurvivin protein expressionTreatment responseN stageKEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Harrington K, Rischin D, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Gumuscu B, Swaby R, Burtness B. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6505-6505. DOI: 10.1200/jco.2020.38.15_suppl.6505.Peer-Reviewed Original ResearchPD-L1 CPSSubsequent anticancer therapyM HNSCCMedian PFS2Subsequent therapyRecurrent/metastatic headNeck squamous cell carcinomaNext-line therapyObjective tumor progressionImmune checkpoint inhibitorsFirst-line therapyKaplan-Meier methodAnticancer therapySquamous cell carcinomaCox regression modelTotal populationKEYNOTE-048Superior OSCheckpoint inhibitorsMetastatic headSystemic therapyComparable safetyCell carcinomaFavorable safetyPatient outcomes
2019
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Rischin D, Harrington K, Greil R, Soulieres D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland A, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Jin F, Gumuscu B, Burtness B. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal Of Clinical Oncology 2019, 37: 6000-6000. DOI: 10.1200/jco.2019.37.15_suppl.6000.Peer-Reviewed Original ResearchCombined positive scorePD-L1 combined positive scoreM HNSCCKEYNOTE-048Median DoRSuperior OSComparable safetyFavorable safetyRecurrent/metastatic headNeck squamous cell carcinomaKEYNOTE-048 trialSecond interim analysisFirst-line therapyPD-L1 testingPhase 3 studySquamous cell carcinomaTotal populationMetastatic headData cutoffSystemic therapyCell carcinomaE. ConclusionInterim analysisAE ratesTumor samplesPoint/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.Peer-Reviewed Original ResearchConceptsDe-escalate treatmentOropharyngeal carcinomaHPV-positive oropharyngeal carcinomaNeck cancer clinical researchNew systemic agentsPhase II trialPhase III trialsTreatment-related morbidityHigh cure ratesCancer clinical researchConcurrent cisplatinII trialOropharynx cancerPrimary surgeryDose intensityIII trialsInstitutional seriesInvasive resectionMultimodality treatmentSystemic agentsSystemic therapyPrimary diseaseCure rateToxic therapiesMultimodality strategy
2015
National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database
Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyComorbidityDatabases, FactualFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPopulation SurveillanceRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesYoung AdultConceptsNational Cancer DatabaseSystemic therapyPalliative therapyTreatment patternsNeck cancerCancer DatabaseClinical trialsMedicaid/uninsured statusCox proportional hazards analysisCommon treatment regimenNational treatment patternsCharlson comorbidity scorePrimary disease siteRetrospective cohort analysisProportional hazards analysisRisk of deathNeck cancer patientsMedicare/Comorbidity scoreMetastatic headOverall survivalSystemic treatmentTreatment regimenDistant metastasisKaplan-Meier
2012
Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer
Mehra R, Ang KK, Burtness B. Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer. Seminars In Radiation Oncology 2012, 22: 194-197. PMID: 22687943, DOI: 10.1016/j.semradonc.2012.03.003.Peer-Reviewed Original ResearchConceptsHPV-positive diseaseNeck carcinomaClinical trialsHuman papillomavirus-negative headOncogenic human papillomavirus (HPV) infectionPack-year smoking historyCurative treatment regimensHPV-negative diseaseHuman Papillomavirus–PositiveHuman papillomavirus infectionSquamous cell headProspective clinical trialsTraditional risk factorsSquamous cell carcinomaHPV-negative headCurrent clinical trialsCombination of radiationIntermediate riskPapillomavirus infectionSmoking historySystemic therapyTreatment regimensCell carcinomaTransoral surgeryNeck cancerMulti-Modality Therapy for Cancer of the Esophagus and GE Junction
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.Peer-Reviewed Original ResearchConceptsGastroesophageal junctionNeoadjuvant platinum-based chemotherapyPostoperative adjuvant chemotherapyPlatinum-based chemotherapyIncidence of adenocarcinomaSubgroup of patientsHigh mortality rateAdjuvant chemotherapyOpinion statementCancersInduction chemotherapyNeoadjuvant treatmentPreoperative chemoradiationDistant recurrenceModality therapySystemic therapyDistal esophagusAdvanced tumorsPredictive biomarkersMortality rateTherapeutic outcomesChemotherapyEsophagusTherapyTherapy deliveryChemoradiation
2006
Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases
Arciero C, Salem R, Lacy J, Sigurdson E, Hoffman J, Watson J, Joseph N, Cooper H, Meropol N, Burtness B. Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases. Journal Of Clinical Oncology 2006, 24: 13523-13523. DOI: 10.1200/jco.2006.24.18_suppl.13523.Peer-Reviewed Original ResearchHepatic metastasectomyPathologic complete responseFOLFOX chemotherapySynchronous metastasesAdverse prognostic featuresHigher lesion numberMedian age 55Multiple wedge resectionsTumor size 1Portal lymph nodesMetastatic colon cancerResidual cancer cellsCurative intentMedian followColorectal metastasesFOLFOX therapyOverall survivalOxaliplatin chemotherapyPathologic responseRadiographic responseResidual cancerSystemic therapyWedge resectionComplete resectionComplete response